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Objectives: Patients with N1 non–small cell lung cancer represent a heterogeneous
population with varying long-term survivals. Prognosis and pattern of recurrence
seem to be particularly affected by the level of lymph node involvement.
Methods: From 1990 to 1995, a total of 1954 consecutive patients underwent
surgical resection for non-small cell lung cancer: 549 (28%) had ipsilateral pulmo-
nary lymph node metastases (N1). The hospital survivors (n  535) were reviewed.
Three levels of lymph node metastases (hilar, interlobar, and lobar) were identified
according to the new Regional Lymph Node Classification for Lung Cancer Staging
and differentiated from lymph node involvement on the basis of direct invasion.
Results: The overall 5-year survival of patients with N1 disease was 40%. Survival
was related in the univariate analysis to T classification, level-type of N1 involve-
ment, number of involved nodes, multilevel involvement, Karnofsky Index, R
status, and adjuvant therapy. In the multivariate analysis, only T classification and
level-type of N1 involvement clearly showed statistical power (P  .000 and P 
.001, respectively). The pattern of cancer relapse according to level-type of N1
involvement differed significantly: hilar N1 disease recurred at distant sites in 41%
of patients and locoregionally in 12% of patients, whereas N1 disease by direct
invasion occurred in 24% and 17% of patients, respectively (P  .030).
Conclusions: Metastases to ipsilateral hilar, interlobar, or both, lymph nodes are
associated with a poorer prognosis compared with metastases in intralobar lymph
nodes or with lymph node involvement by means of direct invasion. Although
surgical resection remains the mainstay of treatment, the high rate of tumor recur-
rence in both groups mandates further randomized studies with multimodality
therapy approaches.
Since the publication of the PORT meta-analysis in 1998,1 whichshowed a detrimental effect or no effect of adjuvant radiotherapy onsurvival of patients with completely resected early-stage non–smallcell lung cancer (NSCLC), it was our concern to better understand thebiologic behavior of early-stage NSCLC and to develop new thera-peutic strategies able to improve the prognosis of patients with this
disease.
Particularly, NSCLC with metastases to the pulmonary (N1) lymph nodes shows
a disappointing prognosis for an early-stage tumor: approximately 40% overall
survival at 5 years compared with approximately 60% for patients with N0 disease.
According to the pathologic staging, 5-year survival was 55% for patients with stage
IIA pT1 N1 disease, 39% for patients with stage IIB pT2 N1 disease, 25% for
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patients with stage IIIA pT3 N1 disease, and approximately
8% for patients with stage IIIB pT4 N1 disease.2
Data from the literature suggest a difference in the long-
term outcome between cancers metastasized to the hilar and
lobar lymph nodes, with the former group being considered
as representing an early N2 disease and the latter as repre-
senting disease that is not yet spreading.3-7
For this purpose, we retrospectively reviewed our popu-
lation of operated patients with pathologic N1 NSCLC
disease to assess whether survival is influenced by level and
type of lymph node involvement and to investigate the
effectiveness of our previous therapeutic concepts for this
group of patients.
Patients and Methods
Between 1990 and 1995, 1954 consecutive patients underwent
surgical resection for NSCLC at the Department of Thoracic
Surgery and Endoscopy of the Ruhrlanklinik, Essen, Germany.
Five hundred forty-nine (28%) patients had involvement of the
ipsilateral pulmonary lymph nodes and were classified as having
pathologic N1 disease. Among them, we observed a 30-day mor-
tality of 2.5% (14 patients), whereas there were 535 hospital
survivors suitable to our prognostic analysis.
In this group the median age was 60.9 years (range, 34-84
years). The male/female distribution was 5.7:1 (454/81) and re-
flects the relative incidence of risk factors (eg, cigarette smoking
and exposure to industrial chemicals) in the general population of
Germany until the early 1990s.
One third of these cancers was diagnosed on routine chest
radiography, and cough, hemoptysis, and pain were leading re-
vealing symptoms in 32%, 15%, and 12% of patients, respectively.
The median duration time of symptoms was 12 weeks (range,
1-100 weeks).
Before the operation, all patients underwent a thorough staging
with chest radiography, chest and upper abdomen (and/or abdomen
sonography) computed tomography (CT), bone scanning, bron-
choscopy, and cervical mediastinoscopy, as well as routine car-
diopulmonary function testing.
According to the revised International System for Staging Lung
Cancer of the International Union Against Cancer (UICC) and the
Regional Lymph Node Classification for Lung Cancer Staging,2,8
clinical stage I disease was found in 297 (55.5%) patients, stage II
disease in 131 (24.5%) patients, stage III disease in 72 (13.5%)
patients, and stage IV disease in 2 (0.5%) patients; the clinical
stage was not reported in 33 records.
Patient characteristics and clinical presentation of the primary
tumor are listed in Table 1.
The operation included, in all but 2 patients, the anatomic
resection of the involved lobe or lung and a systematic lymph node
dissection (upper and lower mediastinal compartments, as well as
subcarinal lymph nodes). The indication to pneumonectomy was a
centrally located tumor or interlobar-hilar lymph node metastasis
with proved extranodal tumor growth, lymphangiosis, or both on
frozen section.
A pneumonectomy was performed in 243 (45.5%) patients, a
sleeve pneumonectomy in 8 (1.5%) patients, a bilobectomy in 37
(6.6%) patients, a lobectomy in 196 (36.7%) patients, a sleeve
lobectomy in 49 (9.3%) patients, and a segmentectomy in 2 (0.4%)
elderly patients with severe comorbidity.
A postoperative pathologic finding of hilar-interlobar extran-
odal metastases or bronchial R1 resection lead, if functionally
suitable, to immediate completion pneumonectomy in 9 (1.7%)
patients and 1 (0.2%) patient, respectively. Our criteria to perform
a completion pneumonectomy are described elsewhere.9
After definitive surgical treatment, complete resection (R0) was
achieved in 436 (82%) patients; a microscopic involvement of
resection margins (R1) was found in 75 (14%) patients, whereas
gross tumor residual masses (R2) could not be resected in 22 (4%)
patients. Anatomic R1 distribution was as follows: hilar fat tissue
in 46 patients, bronchial stump or peribronchial tissue in 15 pa-
tients, mediastinal fat in 4 patients, interlobar surface of the re-
sected lobe in 1 patient, and chest wall in 6 patients. As concerns
TABLE 1. Clinical features of 535 patients with pN1 NSCLC
(1990-1995)
No. %
Age, y
Range 34-84
Median 60.9
Sex
Male/female 454:81 85:15
Symptoms
Asymptomatic 149 33
Cough 147 32
Hemoptysis 68 15
Chest pain 56 12
Other 39 8
Lobe
RUL 155 29
ML 23 4
RLL 94 18
LUL 162 30
LLL 101 19
Location
Central 377 70
Peripheral 158 30
Clinical stage
I 297 55.5
II 131 24.5
III 72 13.5
IV 2 0.5
Unknown 33 6.0
Karnofsky Index
100% 76 14
90-80% 339 63
70% 79 15
Lost data 41 8
FEV1
2.0 L 319 59
1.5-2.0 L 155 29
1.5 L 31 6
Lost data 30 6
FEV1 %
predicted
70% 248 46
50-70% 205 38
50% 52 10
Lost data 30 6
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the R2 resections, macroscopic residual tumors were located in the
mediastinal fat in 11 patients, in the wall of the great vessels in 5
patients, in a vertebral body in 1 patient, in the bronchial stump in
2 patients, and in the chest wall in 3 patients.
Surgical complications are listed in Table 2.
Primary Tumor
The tumor was classified according to the World Health Organi-
zation International Histological Classification of Tumours10 as
squamous cell carcinoma (SCC) in 348 (65%) patients, as adeno-
carcinoma in 139 (26%) patients (including 8 bronchioloalveolar
carcinomas), as anaplastic large cell carcinoma in 26 (5%) pa-
tients, as adenosquamous carcinoma in 18 (3%) patients, and as
other types in 4 (1%) patients. This distribution differs from the
entire cohort of 1954 patients with NSCLC because SSC was
observed in 55% of patients and adenocarcinoma in more than one
third (37%) of patients. As concerns the grading, the tumor was
well differentiated (G1) in 29 (5%) patients, moderately differen-
tiated (G2) in 283 (53%) patients, poorly differentiated (G3) in 193
(36%) patients, and undifferentiated (G4) in 26 (5%) patients; the
grading was unknown in 4 (1%) patients. A lymphatic or blood
vessel invasion was observed in 138 (26%) patients. For the
pathologic T classification of the primary tumor, we retrospec-
tively followed the revised International System for Staging Lung
Cancer of the UICC2: 67 (12%) tumors satisfied the criteria for T1,
287 (54%) for T2, 128 (24%) for T3, and 53 (10%) for T4 disease.
Lymph Node Metastases
We revised the pathologic description of the anatomic location of
lymph node metastases according to the recently published Re-
gional Lymph Node Classification for Lung Cancer Staging.8 Our
pathologists described as “direct invasion of lymph nodes” an
infiltrative extension of viable tumor cells without loss of conti-
nuity from the primary tumor mass to the lymphatic tissue of an
adjacent node. A connection by lymphangiosis carcinomatosa be-
tween the involved lymph node and the primary tumor has not
been considered direct invasion.
One hundred twenty-one (23%) patients had metastases in the
hilar lymph nodes (N1h, station 10) as a more advanced level, 76
(14%) patients in the interlobar nodes (N1i, station 11), and 87
(16%) patients in the peripheral intralobar nodes (N1p, stations 12,
13, and 14), whereas in 251 (47%) patients the lymph node
involvement was through direct extension of the primary tumor on
either hilar, interlobar, or lobar nodes. A multilevel involvement
was observed in 84 (69%) patients of the N1h group and in 45
(59%) patients of the N1i group. Metastasized tumor cells skipped
intralobar, interlobar, or both lymph node stations in 70 (13%)
patients.
Adjuvant radiotherapy was administered to 191 (36%) patients
with either pN1h disease after lobectomy or R1-2 resection mar-
gins; the median radiation dose was 55 Gy. Two (0.5%) patients
underwent adjuvant chemoradiotherapy. Metastases to the interlo-
bar and intralobar nodes and direct lymph node infiltration at any
level were not considered indications for any adjuvant treatment.
Patients who underwent an R0 pneumonectomy for tumor with
hilar node metastasis also did not receive radiotherapy.
The median follow-up time was 36.5 months (range, 1-133
months). One hundred (18.7%) patients had a follow-up of 1 to 12
months, 220 (41.1%) had a follow-up of 13 to 60 months, 173
(32.3%) had a follow-up of 61 to 120 months, and 33 (6.2%) had
a follow-up of more than 120 months. Nine (1.7%) patients were
lost to follow-up.
Statistical Analysis
Cancer recurrence was carefully divided into 2 categories accord-
ing to the site of initial relapse: locoregional or distant. Locore-
gional recurrence was defined as any recurrent disease within the
ipsilateral hemithorax, mediastinum, or supraclavicular lymph
nodes. All other sites of recurrence were considered distant me-
tastases (M). The cause of death was recorded as either cancer
related, other disease, or unknown. Cross-tabulations with the
Pearson 2 test were used for group comparison when appropriate.
Survivals were calculated by using the Kaplan-Meier life-table
method,11 and survival curve comparisons were made by using a
log-rank test,12 in which the initial day of treatment was the day of
the operation. Multivariate analysis was based on the Cox propor-
tional hazards model.13 Analysis was carried out by using a soft-
ware package (Statistical Program for the Social Sciences, release
10.0.7, 2000; SPSS Inc, Chicago, Ill).
Results
Factors Affecting the Pattern of Regional Lymph Node
Involvement
The following clinical and pathologic factors were analyzed
to define any correlation with the level and type of N1
lymph node involvement: sex, type and duration of symp-
toms, anatomic site of the primary tumor, lobe of origin,
clinical stage, histology, grading, and pT classification.
No statistical differences in the pattern of lymph node
involvement were found for sex (male vs female, P .109),
type of symptoms (no symptoms vs cough vs chest pain vs
hemoptysis vs other, P  .063), symptom duration (no
symptoms vs 12 weeks vs 12 weeks, P  .133), lobe of
origin (right upper lobe vs middle lobe vs right lower lobe
vs left upper lobe vs left lower lobe, P  .085), clinical
TABLE 2. Surgical complications after 535 thoracotomies
for N1 NSCLC
No. %
Major complications
Bronchopleural fistula–empyema 15 3
Pneumonia 14 3
Heart failure–infarction 13 2
Rethoracotomy for bleeding 11 2
Respiratory failure–ARDS 5 1
Other 5 1
Minor complications
Cardiac arrhythmia 135 25
Prolonged air leak 55 10
Pleural effusion 8 1
Wound infection 6 1
Other 46 9
ARDS, Adult respiratory distress syndrome.
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stage (stage I vs stage II vs stage III vs stage IV, P  .108),
and grading (G1 vs G2 vs G3 vs G4, P  .402).
On the other hand, the Pearson 2 test revealed a statis-
tically significant correlation for the level and type of N1
involvement with the anatomic tumor site (central vs pe-
ripheral, P  .000), histology (squamous vs adenocarci-
noma vs bronchioloalveolar vs large cell vs adenosquamous
vs other, P .027), pT classification (pT1 vs pT2 vs pT3 vs
pT4, P  .014), and anatomic site (right vs left, P  .039).
In other words, centrally located tumors tend to directly
infiltrate neighboring lymph nodes, metastasize primarily to
the hilar station, or both; peripherally located tumors
showed no preference in the mechanism of lymphatic
spread (Figure 1). Left-sided tumors prefer a direct invasion
or tend to reach the hilar nodes more easily; lymph node
involvement by right-sided tumors is well distributed
among the different levels. SCC arises more frequently in
the wall of the lobar bronchi and is associated with a higher
incidence of direct lymph node involvement compared with
the usually peripherally located adenocarcinoma (Figure 2).
As we observed, the large proportion of patients with direct
lymph node invasion can be explained by a majority of
SCCs (65%) in our population. Finally, the higher the pT
class, the greater the probability of direct infiltration of
lymph nodes, metastases to the hilar nodes, or both (Figure
3).
Overall Survival of Patients With N1 Disease
For all 535 patients with pN1 disease, the cumulative 3-, 5-,
and 10-year survivals were 51%, 40%, and 27%, respec-
tively, with a median survival time of 38 months (Figure 4).
Prognostic Factors for Patients With N1 Disease
Survival curves were compared according to type and du-
ration of symptoms, site of primary tumor, lobe of origin,
Figure 1. Correlation between the site of the primary tumor and the level of lymph node involvement (P  .000).
Figure 2. Correlation between the histology of the primary tumor and the level of lymph node involvement (P 
.027).
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pulmonary function (forced expiratory volume in 1 second
[FEV1] and percent of predicted FEV1), Karnofsky index,
type of operation, blood transfusions, histology, pT classi-
fication, pattern of involvement of N1 lymph nodes (includ-
ing number of involved lymph nodes and node stations), R
status, and adjuvant treatment to individuate factors influ-
encing the prognosis of patients with N1 disease (Table 3).
The log-rank test did not prove any significant correla-
tion with the prognosis for type and duration of symptoms
(P .4371 and P .3717, respectively), site of tumor (P
.8545), lobe of origin (P  .2396), FEV1 and percent of
predicted FEV1 (P  .8354 and P  .2437, respectively),
surgical procedure (P  .2952), administration of blood
transfusions (P  .0666), and histology of the primary
tumor (P  .4833).
Seven factors showed, in the univariate analysis, a sta-
tistically significant correlation with the long-term outcome
of the N1 disease: Karnofsky index, R status, pT classifi-
cation, N status, number of involved lymph node levels,
number of involved lymph nodes, and adjuvant treatment.
Patients were grouped as having a preoperative Karnof-
sky index of 100%, 90% to 80%, or 70% or less. The
actuarial 3-, 5- and 10-year survivals were 54%, 45%, and
35% for the former group; 50%, 41%, and 28% for the
intermediate group; and 44%, 27%, and 15% for the latter
group, respectively (P  .0181).
According to the R status, R0-resected patients had 3-,
5-, and 10-year survivals of 56%, 45%, and 31%, respec-
tively; R1-resected patients had 3-, 5-, and 10-year survivals
of 31%, 20%, and 14%, respectively; and R2-resected pa-
tients had 3-, 5-, and 10-year survivals of 14%, 14% and
10%, respectively (P  .0000).
Pathologic T1 tumors showed a significantly better prog-
nosis (3-, 5-, 10-year survivals of 79%, 65%, and 49%,
respectively) compared with pT2 tumors (56%, 45%, and
29%, respectively), pT3 tumors (38%, 29%, and 20%, re-
Figure 3. Correlation between pT classification and the level of lymph node involvement (P  .014).
Figure 4. Actuarial overall survival for 535 patients with pN1 NSCLC (1990-1995).
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spectively), and pT4 tumors (13%, 8%, and 6%, respective-
ly), with a log-rank test P value of .0000 (Figure 5).
Survival curves according to the pattern of lymph node
involvement also differed significantly (P  .0184): 55%,
45%, and 32% of patients with N1d disease were alive at 3,
5, and 10 years, respectively, whereas corresponding rates
for patients with N1p disease were 55%, 41%, and 28%;
46%, 39%, and 27% for patients with N1i disease; and 42%,
30%, and 20% for patients with N1h disease, respectively
(Figure 6). The results concerning the number of involved
lymph nodes and nodal stations are described below.
Among adjuvant untreated patients, survival at 3, 5, and 10
years was 58%, 47%, and 32%, respectively, and in the
adjuvant radiotherapy group survival was 36%, 23%, and
18%, respectively; none of the 2 patients who received
postoperative radiochemotherapy was alive at 3 years (P 
.0000).
Surprisingly, in the multivariate analysis, neither the
Karnofsky index, the number of involved lymph nodes
and nodal levels, nor adjuvant therapy conserved statis-
tical power (P  .392, P  .566, P  .533, and P  .138,
respectively). The effect of R status on survival ap-
proached statistical relevance (P  .055). The only in-
dependent factors able to influence the long-term prog-
nosis of this population of patients were pT classification
(P  .000) and the type of lymph node involvement (P 
.001).
N1 Involvement and Prognosis
The differentiated survival analysis according to pT classi-
fication demonstrated the prognostic power of the type of
lymph node involvement only for T2 tumors, with 5-year
survivals for the N1d, N1p, N1i, and N1h groups of 54%,
40%, 42%, and 29% and 10-year survivals of 34%, 30%,
31%, and 16%, respectively (P  .0027). Thereafter, the
pattern of N1 involvement showed a trend to influence
prognosis in the population with T3 disease (P  .0589).
The outcome seemed to be independent from the type of N1
involvement in the early (T1, P  .4536) and advanced
stage (T4, P  .2580).
In the overall population a multilevel lymph node me-
tastasis, infiltration, or both correlated with a poorer prog-
nosis compared with the involvement of a single station
(5-year survivals: 27% vs 44%, P  .0002).
We analyzed the importance of the number of involved
lymph nodes independent of the mechanism of tumor inva-
sion: the actuarial 5-year survivals for1, 2 to 5, or more than
5 involved nodes were 49%, 40%, and 30%, respectively
(P  .0145).
Cancer Recurrence
We dispose of detailed information about the cancer-related
clinical course of 358 (67%) of 535 patients. Among them,
163 (45%) patients had a cancer recurrence. The initial
relapse site was distant in 106 (65%) patients and locore-
gional in the remaining 57 (35%) patients. The distribution
Figure 5. Survival curves of patients with N1 disease according to T classification: T1 (), n  67; T2 (open
triangles), n  287; T3 (filled triangles), n  128; T4 (open circles), n  53 (log-rank test, P  .0000).
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of the site of first recurrence among the N1 groups (N1h vs
N1i vs N1p vs N1d) differed significantly, with a prevalence
of distant metastases and locoregional relapse for the N1h
group of 41% and 12%, respectively, and for the N1d group
of 24% and 17%, respectively (P  .030). Among the 73
patients with locoregional recurrence, this arose despite
previous systematic lymphadenectomy in the mediastinal
lymph nodes in 35 (48%) patients and from the bronchial
stump in 38 (52%) patients. No difference was observed in
the distribution of the site of locoregional recurrence ac-
cording to the type of nodal involvement (P  .716).
Among the 119 patients with distant metastases, the relapse
target was the brain in 25 (21%) patients, the lung in 25
(21%) patients, bone in 22 (18%) patients, the liver in 7
(6%) patients, the adrenals in 1 (1%) patient, other sites in
18 (15%) patients, and synchronous multiple organs in 21
(18%) patients. A significant difference was found in the
distribution of the site of distant failure according to the
type of nodal involvement (P  .033, Table 4).
We calculated the probabilities of recurrence in patients
with N1 tumors to be 21% within 1 year of treatment, 42%
within 3 years, and 46% within 5 years.
Discussion
Although the NSCLC with metastases in the ipsilateral
pulmonary lymph nodes (N1; ie, within the boundary of the
pleural reflection) is commonly considered an early-stage
disease, this group of patients experiences a disappointing
prognosis after complete surgical resection, as stated by
numerous authors.2,12-14 Mountain2 reported an overall sur-
vival at 5 years of approximately 40% for patients with pN1
disease compared with approximately 60% for patients with
N0 disease.
According to the UICC stage grouping, patients with
stage IIA pT1N1 disease have a chance of 55% to survive at
5 years, patients with stage IIB pT2 N1 disease of 39%,
patients with stage IIIA pT3 N1 disease of 25%, and pa-
tients with stage IIIB pT4 N1 disease of approximately 8%.2
TABLE 3. Univariate analysis of clinical-pathologic prog-
nostic factors
5-y survival (%) P value
pT classification
T1 65 .0000
T2 45
T3 29
T4 8
Adjuvant therapy
None 47 .0000
Radiotherapy 23
Chemoradiotherapy 0
R status
R0 44 .0001
R1 30
R2 19
Involved node stations
Single station 44 .0002
Multilevel 27
No. of involved nodes
1 49 .0145
2-5 40
5 30
pN classification
N1d 45 .0184
N1p 41
N1i 39
N1h 30
Karnofsky Index
100% 45 .0181
90-80% 41
70% 27
Blood transfusions
No transfusion 36 .0666
Autologous blood 43
Eterologous blood 33
Site
Right 41 .2113
Left 39
Lobe
Upper 39 .2396
Middle 61
Lower 40
FEV1 % predicted
70 40 .2437
50-70 41
50 30
Surgical procedure
Pneumonectomy 44 .2952
Lobectomy-bilobectomy 40
Segmentectomy 0
Duration of symptoms
No symptoms 42 .3717
12 wk 37
12 wk 42
Type of symptoms
No symptoms 41 .4371
Cough 43
Chest pain 28
Hemoptysis 37
Other 41
(Continued)
TABLE 3. Cont’d
5-y survival (%) P value
Histology
Squamous 42 .4833
Adeno 35
Large cell 38
Adenosquamous 33
Other type 50
FEV1, L
2.0 40 .8354
1.5-2.0 39
1.5 36
Location
Peripheral 45 .8545
Central 38
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Previous studies suggest that patients with ipsilateral
pulmonary lymph node metastases represent a heteroge-
neous population, according to the level of lymph node
involvement, as well as the mechanism of invasion (ie,
lymph vessel spread or direct infiltration).3-7,14,15
Metastases to the hilar, interlobar, or both lymph nodes
(stations 10 and 11, according to the new Regional Lymph
Node Classification for Lung Cancer Staging)8 have been
associated with a poorer prognosis compared with metasta-
ses in the intralobar lymph nodes (stations 12, 13, and 14).
Moreover, the long-term outcome of the former group does
not differ significantly from that of patients with single-
station mediastinal lymph node metastases (limited
N2).4,5,7,14,16
We addressed our analysis to define the role of the level,
as well as the mechanism, of lymph node involvement on
the prognosis of patients with N1 disease. Our population
represents a not negligible proportion of patients: 28% of all
patients with operable NSCLC, with an incidence of 90 to
100 patients per year.
The importance of an accurate N staging has been
stressed by several authors to avoid the Will Rogers phe-
nomenon.3,7,14,17,18 The object of our analysis is a purified
series because we accurately excluded N2 disease through
routine cervical mediastinoscopy and an intraoperative sys-
tematic lymph node dissection of the upper and lower
mediastinal compartment, as well as of the subcarinal sta-
tion on both sides, and a dissection of subaortic and para-
aortic nodes on left-sided thoracotomy.
The relatively large proportion of pneumonectomies
(47%) in our series compared with the smaller percentage
(32%) in the entire cohort of 1954 patients could be ex-
plained by considering that more than two thirds of tumors
were located centrally; when feasible, a parenchyma-spar-
ing procedure (ie, sleeve resection) has been preferred
(9.3% of all patients). The intraoperative decision to per-
form a pneumonectomy because of extranodal hilar, inter-
lobar, or both metastases has been made in 29 (5.4%)
patients.
In our study we included patients with incomplete resec-
tion (R1 and R2); most of them (59/99 [60%]) had micro-
scopically diseased margins as a result of lymphangiosis in
Figure 6. Survival curves of patients with N1 disease according to the level and type of lymph node involvement:
N1d (), n  251; N1p (open triangles), n  87; N1i (filled triangles), n  76; Nih (open circles), n  342 (log-rank
test, P  .0184).
TABLE 4. Distribution of sites of distant failure according to
type of lymph node involvement (P  .033)
Site of distant recurrence
N1 type
Hilar
(n  73)
Interlobar
(n  50)
Lobar
(n  62)
Direct
(n  173)
Brain 4 2 6 13
Liver 2 – 2 3
Lung 10 4 3 8
Bone 4 4 8 6
Adrenals 1 – – –
Other 2 2 5 9
Multiple 9 2 1 9
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the hilar fat or peribronchial tissue. As expected, the mul-
tivariate survival analysis demonstrated a major role of
residual tumor on long-term prognosis, although statistical
relevance has not been completely reached (P  .055).
The 5-year overall survival of patients with N1 disease
varies in the literature between 27.2% and 67%, according
to the stage of disease (Table 5).3-7,14,15,17,19-21
The prognostic importance of lymph node involvement
has been underlined by several authors. Yano and col-
leagues,3 in an analysis of 78 patients with pN1 NSCLC,
found that the survival associated with lobar N1 disease was
significantly better than that of patients with hilar-interlobar
N1 disease (64.5% vs 39.7% at 5 years, P  .014). Van
Velzen and associates4 studied the different subsets of the
N1 population separately according to stage. In the first
report on 58 patients with stage IIA pT1 N1 NSCLC, the
5-year survival of patients with N1 direct extension was
superior to the survival of patients with N1 metastases
(68.6% vs 31.2%, P  .0038), and the survival of patients
with N1 disease by means of direct extension was better
than the survival of patients with N1 hilar metastases (P 
.0006) but did not differ from the survival of patients with
lobar metastases. Among 369 patients with stage IIB pT2
N1 NSCLC, the 5-year survival of patients with lobar me-
tastases was superior to that of patients with hilar metastases
(57.3% vs 30.3%, P  .0028) and that of patients with
lymph node involvement by means of direct invasion
(57.3% vs 39.1%, P  .03).5 No significant effect on
survival emerged in T3 N1 or T4 N1 tumors, the prognosis
of which is related only to the completeness of the resection
(P  .0001).6
Riquet and coworkers14 reported 5-year survival to be
significantly better when N1 involvement was intralobar
(levels 12 and 13, n 102) compared with extralobar (hilar)
involvement (levels 10 and 11, n  154; 53.6% vs 38.5%,
P  .02). Survival was not related to the number of in-
volved N1 stations or the type of involvement (direct ex-
tension or metastasis). A difference in the long-term out-
come between hilar and lobar N1 disease failed to be
demonstrated in the analysis of Maggi,19 Martini,17
Asamura,7 and their associates. Our data support the hy-
pothesis that N1 disease is a compound of 2 subgroups: one
metastasized outside the lobe and prognostically compara-
ble with a limited N2 disease and the other confined inside
the lobe by means of metastasis or direct invasion with a
more favorable prognosis (5-year survivals of 30%, 39%,
41%, and 45% for the N1h, N1i, N1p, and N1d groups,
respectively; P  .0184).
The direct extension to adjacent lymph nodes has been
associated with variable prognostic significance. Van Vel-
zen and colleagues4 reported a highly significant difference
between patients with direct invasion and those with hilar
metastases for stage IIA pT1 N1 disease; on the other hand,
they found comparable survivals between patients with di-
rect extension and patients with hilar metastases in stage IIB
pT2 N1 disease.5 These contrasting results might reflect the
related level of lymph node invasion because direct exten-
sion concerns essentially intralobar N1 levels in T1 tumors
and also hilar-interlobar N1 levels in T2 disease according
to both the size and location of the primary tumor. The
mechanism of lymph node invasion did not affect survival
in the series of Riquet and colleagues.14 In the present series
there was no difference in the survival curves of patients
with direct lymph node involvement according to anatomic
level (P  .853), and the N1d disease related to a signifi-
cantly better prognosis than the N1h disease (P  .0184,
log-rank test; P  .001, Cox proportional hazard model).
Martini and colleagues17 observed the best survivals in
TABLE 5. Survival of patients with N1 NSCLC
Author Year No. Stage
5-y survival (%)
Global N1h N1i N1p N1d
Ferguson and coworkers20 1986 34 T1-2 30.2 – – – –
Maggi and coworkers19 1990 157 T1-4 46.1 – – – –
Martini and coworkers17 1992 214 T1-2 39 – – – –
Yano and coworkers3 1994 78 T1-3 49.2 39.7* 64.5 –
Van Velzen and coworkers4 1996 57 T1 45.7 23.3* 55.6 68.6
Van Velzen and coworkers5 1997 369 T2 37.8 30.3* 57.3 39.1
Van Velzen and coworkers6 1999 111 T3-4 27.2 – – – –
Sawyer and coworkers21 1999 107 T1-4 32 – – – –
Riquet and coworkers14 1999 256 T1-4 47.5 38.5* 53.6 53.7 (p)
27.3 (h)
Yoshino and coworkers15 1999 43 T1-2 50.2 47.4* 55 –
Asamura and coworkers7 2000 180 T1-4 67 54 70† –
Marra and coworkers 2003 535 T1-4 40 30 39 41 45
P, Pulmonary, intralobar nodes; h, hilar, extralobar nodes.
*N1h and N1i were analyzed as a single group.
†N1i and N1p were analyzed as a single group.
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patients with stage II NSCLC who had a single node in-
volved (P .016) and tumors 3 cm or less in diameter (P
.021), with a 5-year survival of 48% for patients with a
combination of these favorable features. The administration
of adjuvant radiotherapy lead to a worse prognosis (P 
.000035).
The role of the number of involved nodes on prognosis
has been confirmed by our univariate analysis, with a more
favorable long-term outcome when only one lymph node
was colonized by tumor compared with multiple lymph
node metastases (P .0145). Similarly, in our series single-
station N1 disease had a better prognosis than multilevel
disease (P  .0002).
Other prognostic factors that have been demonstrated to
affect the outcome of patients with N1 disease were age,5 T
stage,21 histology,6 visceral pleura involvement,5 positive
bronchoscopic findings,21 the number of dissected lymph
nodes,21 and macroscopic nodal metastases.15
The modality of recurrence seemed to be affected by the
level and type of N1 involvement in the series of Yano and
colleagues,3 with the brain being the most frequent site of
distant metastasis in lobar N1 disease and the lungs being
the most frequent site in hilar N1 disease. We also observed
different patterns of cancer relapse according to nodal in-
volvement: N1h tumors tended to recur at distant sites, with
preference for the controlateral lung, whereas the most
frequent target for N1d tumors was the brain (P  .030).
In analyzing 58 patients with pT1 N1 NSCLC, Van
Velzen and associates4 observed that relapses were more
frequent in patients with hilar metastases than in patients
with lobar metastases or with involvement by direct exten-
sion (56% vs 33% vs 22%). In the hilar metastasis group the
most common pattern of relapse was distant metastases. No
difference in the modality of relapse on the basis of the level
of N1 disease was detected by Riquet and colleagues.19
According to Martini and coworkers,17 local-regional recur-
rence was more frequent in patients with squamous carci-
noma, whereas distant metastases were more commonly
seen in adenocarcinomas (87% of patients with metastases),
with the brain as the most frequent site.
Surgical resection is considered thus far the treatment of
choice for patients with N1 disease, but a great proportion of
these patients experiences a cancer recurrence, either lo-
coregional or distant. The best adjuvant treatment to asso-
ciate with surgical resection is still a matter of debate.
The PORT meta-analysis reviewed data on 2128 patients
with stage I to III disease and completely resected tumors
from 9 randomized trials of postoperative radiotherapy ver-
sus surgery alone. The results showed a significant adverse
effect of radiotherapy on survival, with a greater negative
influence on patients with stage I to II, N0 to N1 disease.1
This could be explained by considering that the risk of
systemic recurrence is dominant in all stages, minimizing
the potential effect of radiotherapy on survival. The ratio-
nale for thoracic radiotherapy increases with advancing
disease stage because the risk of intrathoracic recurrence
increases. In patients with early-stage disease, the morbidity
of radiotherapy outweighs the benefits regarding cancer-
specific survival, leading to an overall detrimental effect.22
Our observation of a worse prognosis of patients treated
with adjuvant radiotherapy compared with untreated pa-
tients (23% vs 47% 5-year survival, P  .0001) confirms
this opinion, although the unfavorable prognostic weight of
radiotherapy disappeared on the multivariate analysis (P 
.138).
Adjuvant chemotherapy has been expected to gain sur-
vival improvement for patients with N1 disease. However,
despite the compelling rationale for adjuvant systemic ther-
apy in patients with resected node-positive NSCLC, it has
been difficult to identify an effective regimen with present
chemotherapeutic drugs. Randomized trials and meta-anal-
yses of these trials have not found combined chemoradio-
therapy to prolong survival in patients with completely
resected stage I and II NSCLC.23-26
Chemotherapy and chemoradiotherapy in a neoadjuvant
setting are promising modalities, as shown by 2 randomized
and several phase II clinical trials in locally advanced dis-
ease,27-30 but phase III studies in early-stage NSCLC are
needed to define the optimal schedule and timing of sys-
temic therapy.31
The present retrospective study confirms that N1 NSCLC
is a compound of an intralobar subset that has a relatively
more favorable prognosis and a hilar-interlobar subset that
behaves like limited N2 disease. The direct infiltration of
neighboring lymph nodes by the primary tumor tends to
worsen the prognosis, as compared with N0 NSCLC, and
could be interpreted like a gate for the tumor to accede to
the lymphatic circulation. Surgical resection remains the
mainstay of therapy. Because the most common pattern of
relapse after the operation is distant metastases in all groups,
systemic therapy is mandatory to treat occult metastases and
to provide survival advantages. The optimal timing, as well
as the schedule of chemotherapy, should be investigated in
future trials. As emerges from the PORT meta-analysis,1
radiotherapy could be able to prevent the occurrence of
most local relapses, but toxicity could outweigh the benefits
regarding cancer-specific survival in patients at relatively
low risk for locoregional recurrence.
We acknowledge the assistance of Mrs Barbara Daut in data
collection.
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